Acculi Labs Pvt Ltd is thrilled to announce a significant milestone in its journey toward transforming health monitoring with the successful raising of $1,500,000 in funding. This capital infusion will be instrumental in further developing Lyfas, the company鈥檚 groundbreaking digital biomarker and diagnostic tool powered by innovative photoplethysmography (PPG) technology. Designed to revolutionize how health metrics are gathered, Lyfas detects subtle changes in blood volume and the reflected light spectrum of blood chemistry within the microvascular bed of tissue. Through this non-invasive, personalized, and remote monitoring system, Lyfas can continuously assess vital functional biomarkers such as pulse rate variability, cardiac dynamics, autonomic nervous function, and lung function, providing crucial data that informs life-saving healthcare decisions.
The newly acquired funds will enhance Acculi Labs' research capabilities, enabling the refinement of Lyfas's predictive analytics to better forecast critical health events, including heart attacks and strokes. By offering clinicians and patients an empowering tool for longitudinal health monitoring, Lyfas not only aims to improve individual health outcomes but also to enable large-scale population health assessments at a cost-effective rate. The proactive use of this data can facilitate the identification of chronic conditions and help mitigate the risks associated with debilitating diseases like hypertension and diabetes. This funding marks a pivotal step in Acculi Labs' mission to partner with healthcare professionals and empower patients, fostering a partnership that ensures proactive self-management of health and ultimately, an enhanced quality of life. As we continue to innovate, we remain committed to driving positive changes in health management through advanced technology.
